NRX Pharmaceuticals Inc (NRXP) is a Healthcare · Biotechnology company listed on NASDAQ. Price $3.32 (-2.06%), Market cap $0.10B, 52-week low–high $1.68 ~ $3.67.
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides p
Financial statements, price targets, institutional (13F) holdings and related news for NRX Pharmaceuticals Inc are updated in real time on BlackAll Trade.
NRX Pharmaceuticals Inc trades at $3.32 (-2.06%). Real-time quotes and charts are available on BlackAll Trade.
NRX Pharmaceuticals Inc has a market cap of about $0.10B.
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress